PANTR1: A Potential Drug Target and Biomarker (G100506421)

Target Name: PANTR1

NCBI ID: G100506421

PANTR1

PANTR1: A Potential Drug Target and Biomarker

Pancreatic cancer is a leading cause of cancer-related deaths worldwide, with a poor treatment outcomes and high mortality rates. The discovery of potential drug targets and biomarkers for pancreatic cancer could lead to new and more effective treatments. One such potential drug target and biomarker is PANTR1, which has been identified as a potential target for pancreatic cancer.

PANTR1 is a gene that encodes a protein known as PANCR1 (padding domain-containing RNA-binding protein 1). PANCR1 is expressed in various tissues, including pancreas, and has been shown to play a role in pancreatic development, function, and cancer progression. PANCR1 has also been shown to be involved in cell signaling pathways, including the TGF-β pathway.

The TGF-β pathway is a well-established pathway involved in various cellular processes, including cell growth, differentiation, and cancer progression. PANCR1 has been shown to be a positive regulator of TGF-β signaling in pancreatic cancer cells. This means that when PANCR1 is activated, it can promote the growth, differentiation, and cancer progression of pancreatic cancer cells.

In pancreatic cancer, the imbalance of TGF-β signaling can lead to the development and progression of cancer. Therefore, targeting PANCR1 with drugs that can inhibit its activity could be an effective strategy for the treatment of pancreatic cancer.

PANTR1 has also been shown to be involved in the regulation of pancreatic cancer cell apoptosis (programmed cell death). Apoptosis is a natural process that helps eliminate damaged or dysfunctional cells in the body. However, in pancreatic cancer, the imbalance of cell proliferation and apoptosis can promote the growth and progression of cancer cells.

In conclusion, the identification of PANTR1 as a potential drug target and biomarker for pancreatic cancer highlights the potential for new and more effective treatments. Further research is needed to fully understand the role of PANCR1 in pancreatic cancer and to develop effective therapies that target this protein. By identifying and targeting PANTR1, researchers hope to improve treatment outcomes for pancreatic cancer.

Protein Name: POU3F3 Adjacent Non-coding Transcript 1

The "PANTR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PANTR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets